2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Diseases, Hemoglobinopathies, Thalassemia, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

4233 An open-label Phase I study of JAK inhibitor, ruxolitinib, with and without CTLA-4 ig, abatacept, for the prophylaxis of graft-versus-host disease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation

Rebecca Lynn Cunningham, MD, PhD, Feng Gao, MD, PhD, MPH, MS2, Jeffrey King3, Maggie Nash4, Autumn House5, Zachary D. Crees, MD6, Armin Ghobadi, MD7, Samuel Urrutia, MD, MS8, Meagan A. Jacoby, MD, PhD9, Geoffrey L. Uy, MD10, Iskra Pusic, MD MSCI11, Julie Ritchey12, John F. DiPersio, MD13, Ramzi Abboud, MD14
1 Washington University in St. Louis, St. Louis, Missouri, United States
2 Washington University in St. Louis, St. Louis, Missouri, United States
3 Washington University in St. Louis, St. Louis, Missouri, United States
4 Washington University in St. Louis, St. Louis, Missouri, United States
5 Washington University in St. Louis, St. Louis, Missouri, United States
6 Washington University in St. Louis, St. Louis, Missouri, United States
7 Washington University in St. Louis, St. Louis, Missouri, United States
8 Washington University in St. Louis, St. Louis, Missouri, United States
9 Washington University in St. Louis, St. Louis, Missouri, United States
10 Washington University in St. Louis, St. Louis, Missouri, United States
11 Washington University in St. Louis, St. Louis, Missouri, United States
12 Washington University in St. Louis, St. Louis, Missouri, United States
13 Washington University in St. Louis, St. Louis, Missouri, United States
14 Washington University in St. Louis, St. Louis, Missouri, United States

Introduction: Graft-versus-host disease (GVHD) is a common complication of haploidentical peripheral blood hematopoietic cell transplantation (PB haplo-HCT) and results in high morbidity and mortality in steroid-refractory cases. Our prior study demonstrated that the selective JAK1 inhibitor, itacitinib, was well-tolerated, prevented grades III-IV acute GVHD (aGVHD) and severe cytokine release syndrome (CRS), and was associated with low rates of chronic GVHD (cGVHD) in patients undergoing PB haplo-HCT. Given JAK/STAT pathways are critical for the pathogenesis of GVHD and CRS, and based upon data from preclinical mouse allotransplant studies, we hypothesize that JAK1/2 inhibition, with and without a CTLA-4 Ig, will decrease rates of GVHD without compromising the graft vs leukemia effect or engraftment. We performed a clinical trial using the JAK1/2 inhibitor, ruxolitinib, with and without abatacept, for GVHD prophylaxis in patients undergoing PB haplo-HCT. Here, we report clinical outcomes of regimen 1 with ruxolitinib prophylaxis in our phase I study (NCT06008808).

Methods: Forty patients with hematologic malignancies undergoing PB haplo-HCT will be enrolled in this study. Both myeloablative and reduced intensity conditioning regimens are permitted, and all patients are treated with post-transplant cyclophosphamide 50 mg/kg (days +3, +4). Enrollment of regimen 1 was sequentially completed before enrollment of regimen 2. Regimen 1 – ruxolitinib alone: On day -3, patients start ruxolitinib 5 mg BID titrating up to 10 mg BID based upon target cell counts until day +180, followed by a taper. Patients also receive mycophenolate mofetil 15 mg/kg TID on days +5-28 and tacrolimus on days +5 to at least day +100 with target serum level of 3-7 ng/mL. Regimen 2 – ruxolitinib + abatacept: Patients receive ruxolitinib as in regimen 1, with removal of mycophenolate mofetil, and receive abatacept 10 mg/kg on days +5, +14, +28, and +56. Tacrolimus is administered on days +5-60 with target serum level 3-7 ng/mL. The primary endpoint is safety as assessed by cumulative incidence of graft failure at day +35, cumulative incidence of grade III-IV aGVHD at day +100, and number of patients who experience CRS and grade of CRS through day 14. Secondary endpoints include NRM, incidence of grade II-IV aGVHD, incidence of cGVHD, relapse incidence, and overall survival (OS).

Results: Twenty-one patients who underwent PB haplo-HCT between July 2024 and December 2025 were enrolled to receive regimen 1 with ruxolitinib-only prophylaxis. Median age at transplant was 61.3 years (range 40-73 years) and 17 patients are male. Diagnoses were AML, ALL, MDS, and NHL with six patients having either complex cytogenetics and/or TP53 mutations. Median follow up is 313 days with 15/21 patients beyond 180 days. Median time to neutrophil engraftment was 17.5 days (95% CI 16.5-21.6), and 30 days for platelet engraftment (95% CI 25.7-35.4). There were no cases of grade III or IV GVHD. The incidence of any grade aGVHD through day 180 was 28% (95% CI 11-49%) with one case of grade II aGVHD. There have been two cases of cGVHD. There were no cases of grade III or IV CRS. GVHD-free relapse free survival (GRFS) was 46.4% (95% CI 24.4%-66.1%). By day 180, 9.5% of patients had relapsed disease (95% CI 1.5-27%), and 19% of patients relapsed by day 360 (95% CI 5.7-39%) with a relapse free survival of 46.6% (95% CI 24.4%-66.1%). There were seven cases of NRM: conditioning related toxicity and encephalopathy with multiorgan failure at day +115, hypoxic respiratory failure without clear infectious etiology on day +179, an aspiration event following engraftment on day +21, suicide at day +265, respiratory failure with pulmonary infections including influenza and Acremonium and E. faecium bacteremia on day +85, HHV6 encephalitis and CMV pneumonitis on day +31, and renal failure on day +96.  OS at 6 months was 76% (95% CI 51.9%-89.3%) and 54.9% at one year (95% CI 30.9%-73.6%). Of evaluable patients, 16/16 had >95% chimerism at day 100. Regimen 2 with both ruxolitinib and abatacept is now open for enrollment.

Conclusions: We report on outcomes of regimen 1 using ruxolitinib for GVHD prophylaxis in PB haplo-HCT. Ruxolitinib was not associated with grade III-IV GVHD, grade II or higher CRS, or engraftment failure at day 100 in evaluable patients. Unexpectedly, seven patients experienced NRM.

Rebecca Lynn Cunningham, MD, PhD: No relevant conflicts of interest to declare.